Streptococcus agalactiae or Group B streptococci (GBS) usually colonizes gastrointestinal, respiratory, and urogenital human tracts causing diverse types of infections. Urogenital colonization of pregnant women with GBS is a critical risk factor for developing invasive neonatal disease, being the antimicrobial prophylaxis recommended during the delivery [1] . GBS is traditionally considered to be a neonatal pathogen although recently an increasing incidence of infections among American adults, especially those patients with underlying medical conditions, has been observed [2] . Macrolides and lincosamides are the recommended second-line agents and also a therapeutic alternative for patients with penicillin allergy. Resistance to lincosamides in S. agalactiae is commonly mediated by Erm-type methylases, which confer cross-resistance to macrolide, lincosamide and streptogramins B [3] [4] [5] . Recently, LnuB (also named as LinB) and LnuC lincosamide nucleotidyl-transferase enzymes were described, in three and one S. agalactiae isolates, respectively [3] [4] [5] . Erythromycin-and clindamycinresistance in GBS increased from 7 (1) , and from three distant cities. The isolates displayed the L-phenotype and were recovered from prenatal recto-vaginal screening cultures (n = 5) and a urine sample (n = 1) ( Table 1) . Disk diffusion and minimal inhibitory concentration by agar dilution were performed according to CLSI guidelines [6] . Detection of mefA, ermA, ermB, lnuA and lnuB genes was performed by PCR, and DNA sequence was determined using the ABI 3500 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Clonal relationship was evaluated by ApaI-PFGE using the following conditions: initial and final pulsed times were 2 and 20 seconds, respectively, 1% agarose gel, 6 V/cm during 20 hs, and a CHEF-DRIII apparatus. DNA patterns were analyzed using Bionumerics software (Sint-Martens-Latem, Belgium) using Dice coefficient and 1% of tolerance, and the relationships were established according to Tenover's criteria [7] . Conjugation assays, 1:1 donor/acceptor ratio, were performed using S. agalactiae M6395 and Staphylococcus aureus RN4220 as recipient strains, both susceptible to macrolides and lincosamides, and S. agalactiae M6390 as the donor strain. Brain heart infusion agar plates used for conjugation and selection were incubated at 35º C for 24 hours.
The six S. agalactiae isolates showing Lphenotype were susceptible to penicillin, cefotaxime, erythromycin, ofloxacin, levofloxacin and vancomycin, while three strains were resistant to tetracycline by disk diffusion. A modified triple diskdiffusion assay with clindamycin-erythromycinlincomycin was performed [6] . Absences of inhibitory zones were observed around clindamycin and lincomycin disks; no inducible pattern was detected. Minimal inhibitory concentrations (MIC) of the six S. agalactiae isolates were susceptible to erythromycin, MIC = 0.06-0.12mg/L, and azithromycin, MIC = 0.25mg/L, but resistant to clindamycin, MIC = 4mg/L, and lincomycin, MIC = 64-128mg/L (Table 1 ). All isolates were PCR positive only for lnuB gene, and were confirmed by DNA sequencing (Accession number, HM209466). No mutation on L4 and L22 ribosomal proteins or 23S rRNA, domains II and V, were detected in the first recovered isolate (M6390), discarding additional mechanisms of resistance. Four clones were discriminated by ApaI-PFGE (n): A (3), B (1), C (1) and D (1) (Figure 1 ). Domain V of a representative isolate of the other clonal types, A (M6640), C (M6637) and D (M6641), were also sequenced and no mutations were found. Clones A and D were detected in FER hospital, while clones B and C were from PYR and RAW hospitals, respectively (Table  1) . Conjugation assays were unsuccessful under different experimental conditions and using two recipient strains. Although we can not discard methodological restrictions, the lnuB gene could be harboured in a cryptic plasmid or inserted in the chromosome as was described in Enterococcus faecium HM1025 [8] . In our country, the level of macrolide resistance is not only alarming in GBS, but also it has been increasing in invasive pediatric S. pneumoniae from 6% in the period of 1998-2001 to 16.4% in 2006, while no significant differences were observed in Group A streptococci during the last years, 4.7% in 2005 and 3.6% in 2007 [9; WHONETArgentina unpublished data].
Although different authors described S. agalactiae clinical isolates expressing an Lphenotype in only three cases that the lnuB gene was detected, two strains were from Canada and one from Additionally, lnuB gene was also described in seven strains of Streptococcus dysgalactiae ssp. equisimilis from pig samples and in four Streptococcus uberis recovered from milk samples [13, 14] . These data suggest that animals could be a potential reservoir of the lnuB gene.
In conclusion, we describe for the first time the polyclonal emergence of S. agalactiae harbouring the lnuB gene in Latin-America. Fortunately, S. agalactiae isolates expressing lnuB gene were easily detected in the clinical laboratory applying disk diffusion or dilution methods. Continuous surveillance of antibiotic susceptibility is necessary not only to detect known resistance phenotypes, but also to identify newly acquired resistance mechanisms.
